Abstract
2758 Is there a survival benefit for patients who receive post-operative adjuvant chemotherapy following secondary cytoreductive surgery (SCRS) for recurrent epithelial ovarian cancer (EOC)?
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
